Boala Parkinson și tulburări de mișcare.
64 de articoleResearchers at Texas A&M University developed a novel mouse model using Theiler's murine encephalomyelitis virus (TMEV) infection to generate Parkinson's disease symptoms without genetic modification or toxic injection. This approach provides a more naturalistic animal model to investigate the hypothesis that viral infection may trigger Parkinson's disease development in humans.
This study used corneal confocal microscopy to detect corneal nerve loss as a potential biomarker for neurodegeneration in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Corneal nerve fiber density was significantly reduced in all three patient groups compared to healthy controls, with the most pronounced changes in multiple system atrophy, suggesting this imaging technique may help differentiate these neurodegenerative conditions.
Rhythmic auditory stimulation (RAS) demonstrates effectiveness in improving gait, balance, and fall prevention in Parkinson's disease through mechanisms involving neural entrainment and oscillatory brain coupling. Research suggests RAS-based interventions may address additional PD symptoms and extend to atypical parkinsonian disorders, though further study is warranted.
UCLA researchers found that long-term exposure to the pesticide chlorpyrifos significantly increases Parkinson's disease risk, with exposed individuals showing more than twice the likelihood of developing the condition. Laboratory studies demonstrated the chemical damages dopamine neurons and impairs the brain's ability to clear toxic protein aggregates.
Researchers developed a method to identify which genetic networks discovered in model organisms (yeast, neurons, mice) are most relevant to human Parkinson's disease. This translational genetics approach bridges the gap between basic research findings and actual human disease mechanisms.
This cross-sectional study of 80 Parkinson's patients examined relationships between objectively measured daily physical activity (step count) and symptom severity using wearable devices over 6 weeks. Higher daily activity was associated with significantly reduced bradykinesia and paradoxically increased mild dyskinesia, supporting the role of physical activity in managing Parkinson's motor symptoms.
This review examines how wartime conditions—including traumatic brain injury, chronic stress, toxin exposure, and healthcare disruption—influence Parkinson's disease risk and management outcomes. The paper identifies critical gaps in knowledge regarding PD progression in conflict-affected populations and calls for evidence-based humanitarian protocols and telemedicine approaches for neurological care during conflict.
Depression affects over one-third of Parkinson's disease patients with significant diagnostic challenges due to symptom overlap between the conditions. Treatment involves pharmacotherapy (SSRIs, SNRIs, tricyclics) and psychotherapy (CBT, interpersonal therapy) adapted for PD-specific vulnerabilities, though access to specialized mental health care remains limited.
GLP-1 receptor agonists, originally developed for diabetes and obesity, show neuroprotective properties in preclinical models of movement disorders by modulating neuroinflammation, oxidative stress, and protein aggregation. Clinical evidence is most advanced in Parkinson's disease, though early promise from exenatide and lixisenatide trials was not confirmed in larger phase III studies, with preliminary signals emerging in other movement disorders.
This PET neuroimaging study examined cholinergic terminal density in 16 patients with isolated REM sleep behavior disorder (iRBD, a prodromal stage of Parkinson's disease) compared to 12 Parkinson's patients and 18 controls. Both patient groups showed similar cortical cholinergic denervation (11-12% reduction) with distinct regional patterns, while iRBD showed associations between lower cholinergic uptake and impaired executive/visuospatial function.
Official clinical guidance from the Movement Disorder Society providing an evidence-based biological definition, staging system, and classification framework for Parkinson's disease. This statement establishes standardized diagnostic and prognostic criteria for specialists managing the condition.
This longitudinal study tracked 258 newly diagnosed Parkinson's disease patients over five years, identifying three cognitive trajectory groups: cognitively normal, remitting decline, and progressive decline. Progressive cognitive decline was associated with depression, REM sleep behavior disorder, older age, lower education, elevated neurofilament biomarkers, and accelerated hippocampal volume loss, while remitting decline showed intermediate outcomes and olfactory dysfunction.
Researchers developed a screening tool to improve timely referral of Parkinson's disease patients to specialized centers for device-aided therapies, based on analysis of 259 patients across 8 hospitals. The tool identified response fluctuations and dyskinesias as key predictors and outperformed existing 5-2-1 referral criteria in clinical decision-making.
This research explores metabotropic glutamate receptors (mGluRs) as potential therapeutic targets for managing Parkinson's disease symptoms. The approach focuses on modulating glutamatergic signaling pathways to address motor dysfunction and neurodegeneration associated with the condition.
This preclinical study examined how intermittent theta-burst stimulation (iTBS), a noninvasive brain stimulation technique, modulates astrocyte function and glutamate homeostasis in a rat model of Parkinson's disease. Results showed iTBS improved striatal astrocyte responses, restored glutamate transporter function, and enhanced motor recovery, suggesting astrocyte modulation contributes to iTBS therapeutic effects.
This review examines advances in Parkinson's disease biomarkers, particularly α-synuclein detection using immunodetection and emerging seed amplification assays in cerebrospinal fluid and blood. Seed amplification assays show promise as more reliable diagnostic tools with improved accuracy, representing a significant advancement toward non-invasive biomarker testing for disease diagnosis and progression monitoring.
This review examines neuromelanin's complex involvement in Parkinson's disease, highlighting its paradoxical neuroprotective properties as an antioxidant alongside its harmful effects through mitochondrial dysfunction and oxidative stress when accumulated. Emerging therapeutic strategies targeting neuromelanin accumulation include antioxidant therapy, proteostasis enhancement, ion chelation, and immunotherapy, though clinical trial results remain mixed.
This prospective study assessed the prevalence of blepharoclonus (eyelid fluttering) in 75 Parkinson's disease patients and 10 with atypical parkinsonism, finding it present in 84% of PD cases and 60% of synucleinopathy cases but absent in non-synucleinopathy parkinsonian syndromes. The findings suggest blepharoclonus may have diagnostic utility in differentiating synucleinopathy-associated parkinsonism from other parkinsonian conditions.
